AR122411A1 - Radioinmunoconjugados dirigidos a tem-1 y sus usos - Google Patents
Radioinmunoconjugados dirigidos a tem-1 y sus usosInfo
- Publication number
- AR122411A1 AR122411A1 ARP210100884A ARP210100884A AR122411A1 AR 122411 A1 AR122411 A1 AR 122411A1 AR P210100884 A ARP210100884 A AR P210100884A AR P210100884 A ARP210100884 A AR P210100884A AR 122411 A1 AR122411 A1 AR 122411A1
- Authority
- AR
- Argentina
- Prior art keywords
- radioimmunoconjugates
- tem
- targeted
- pharmaceutical compositions
- radioimmunoconjugate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
- A61N2005/1019—Sources therefor
- A61N2005/1021—Radioactive fluid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Optics & Photonics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063006040P | 2020-04-06 | 2020-04-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR122411A1 true AR122411A1 (es) | 2022-09-07 |
Family
ID=78022984
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210100884A AR122411A1 (es) | 2020-04-06 | 2021-04-06 | Radioinmunoconjugados dirigidos a tem-1 y sus usos |
Country Status (3)
| Country | Link |
|---|---|
| AR (1) | AR122411A1 (zh) |
| TW (1) | TW202204336A (zh) |
| WO (1) | WO2021207086A1 (zh) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3233733A1 (en) * | 2021-09-29 | 2023-04-06 | National Research Council Of Canada | Egfrviii-targeted compounds and uses thereof |
| WO2023122588A2 (en) * | 2021-12-20 | 2023-06-29 | Fusion Pharmaceuticals Inc. | Egfr-cmet–targeted compounds and uses thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3202788A1 (en) * | 2016-02-05 | 2017-08-09 | MediaPharma S.r.l. | Endosialin-binding antibody |
| JP2022511471A (ja) * | 2018-12-03 | 2022-01-31 | フュージョン ファーマシューティカルズ インコーポレイテッド | 放射性免疫複合体とｄｎａの損傷および修復阻害剤の併用療法 |
-
2021
- 2021-04-05 WO PCT/US2021/025800 patent/WO2021207086A1/en active Application Filing
- 2021-04-06 TW TW110112424A patent/TW202204336A/zh unknown
- 2021-04-06 AR ARP210100884A patent/AR122411A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021207086A1 (en) | 2021-10-14 |
| TW202204336A (zh) | 2022-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR122411A1 (es) | Radioinmunoconjugados dirigidos a tem-1 y sus usos | |
| CL2022000271A1 (es) | Inhibidores de la fosfatasa shp2 de pirazolo(3,4-b)pirazina. | |
| UY38880A (es) | Degradadores bifuncionales de brd9 y sus métodos de uso | |
| AR035936A1 (es) | Inhibidores de metaloproteinasas de matriz piridinica, derivados de piridina, composiciones farmaceuticas y usos de los mismos en la fabricacion de medicamentos | |
| DOP2021000017A (es) | Compuestos de pirimidina y composiciones farmaceuticas para prevenir o tratar cánceres que incluyen los mismos | |
| UY28708A1 (es) | Heterociclos sustituídos y usos de los mismos | |
| CL2021002378A1 (es) | Conjugados de anticuerpo modulador de empalme - fármaco y métodos de uso. (divisional de solicitud 202003117) | |
| CO2021009882A2 (es) | Inhibidores aza-heterobicíclicos de mat2a y métodos de uso en el tratamiento de cáncer | |
| UY26456A1 (es) | Compuestos que fijan la estructura g-cuadruplex de los telomeros, triazinas de aplicación de dichos compuestos, la utilización de dichos compuestos como productos farmacéuticos y las asociaciones terapéuticas que los incluyen. | |
| UY38096A (es) | Inhibidores de arginasa y sus métodos de uso | |
| AR108461A1 (es) | Compuestos imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer | |
| AR126701A1 (es) | Derivados de n-ciclopropilpirido[4,3-d]pirimidin-4-amina y usos de los mismos | |
| UY38625A (es) | Compuestos y su uso en el tratamiento del cáncer | |
| CL2021001388A1 (es) | Compuestos útiles en la terapia para el vih | |
| CO2024001367A2 (es) | Compuestos antivirales | |
| AR124078A1 (es) | Método para el tratamiento de la enfermedad de parkinson | |
| CO2022008690A2 (es) | Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso | |
| ECSP19084722A (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias | |
| AR121643A1 (es) | Radioinmunoconjugados dirigidos a fgfr3 y usos de estos | |
| AR126251A1 (es) | Inhibidores de cdk2 | |
| CR9539A (es) | 4-anilino-3-quinolinocarbonitrilos para el tratamiento de cancer | |
| CO2021017202A2 (es) | Compuestos tricíclicos | |
| CO2021002980A2 (es) | Formulaciones de dendrímeros | |
| AR127556A1 (es) | Métodos para tratar el cáncer utilizando un radioinmunoconjugado | |
| AR124059A2 (es) | Conjugados de anticuerpo modulador de empalme-fármaco y métodos de uso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |